How do you approach use of tamoxifen for chemo-prevention in post-menopausal women with non-BRCA germline mutations?
For instance, patients with ATM mutations
Answer from: Medical Oncologist at Academic Institution
I am not aware of any prospective studies specifically looking at non-BRCA mutations and tamoxifen’s role in chemoprevention in this population, although some retrospective studies in BRCA mutated patients have demonstrated a significant beneficial effect.The NSABP breast cancer prevention tri...
Sign in or Register to read more